Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.825 EUR | +0.18% | -2.59% | +3.86% |
Mar. 15 | Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development | MT |
2023 | Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results | MT |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 5.633 | 3.049 | 0.5368 | 2.684 | 7.754 | 5.103 |
Enterprise Value (EV) 1 | 6.751 | 5.251 | 3.264 | 5.311 | 7.268 | 4.682 |
P/E ratio | -0.54 x | -0.52 x | -0.14 x | 16.7 x | 4.78 x | 14 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.64 x | 0.74 x | 0.33 x | 1.55 x | 4.02 x | 2.69 x |
EV / Revenue | 0.76 x | 1.28 x | 2 x | 3.06 x | 3.77 x | 2.47 x |
EV / EBITDA | -5.58 x | -4.89 x | -10.2 x | 19.2 x | 18.6 x | 9.26 x |
EV / FCF | -2.25 x | -1.67 x | 8.34 x | -1.74 x | -1.67 x | 44.1 x |
FCF Yield | -44.5% | -59.8% | 12% | -57.5% | -59.8% | 2.27% |
Price to Book | 0.9 x | 6.5 x | -0.16 x | -0.84 x | -4.91 x | -4.24 x |
Nbr of stocks (in thousands) | 3,314 | 3,314 | 3,314 | 3,314 | 3,314 | 3,314 |
Reference price 2 | 1.700 | 0.9200 | 0.1620 | 0.8100 | 2.340 | 1.540 |
Announcement Date | 4/30/18 | 4/30/19 | 6/2/20 | 5/21/21 | 4/29/22 | 4/27/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 8.856 | 4.111 | 1.634 | 1.736 | 1.929 | 1.896 |
EBITDA 1 | -1.21 | -1.075 | -0.3206 | 0.2771 | 0.3916 | 0.5059 |
EBIT 1 | -1.858 | -1.324 | -0.4672 | 0.2051 | 0.282 | 0.3708 |
Operating Margin | -20.98% | -32.2% | -28.59% | 11.81% | 14.61% | 19.56% |
Earnings before Tax (EBT) 1 | -9.886 | -5.695 | -3.462 | 0.1696 | 0.3403 | 0.3657 |
Net income 1 | -10.37 | -5.811 | -3.834 | 0.1609 | 1.622 | 0.3767 |
Net margin | -117.05% | -141.36% | -234.58% | 9.27% | 84.09% | 19.87% |
EPS 2 | -3.130 | -1.754 | -1.160 | 0.0486 | 0.4896 | 0.1100 |
Free Cash Flow 1 | -3.004 | -3.138 | 0.3914 | -3.055 | -4.347 | 0.106 |
FCF margin | -33.92% | -76.34% | 23.95% | -176% | -225.29% | 5.59% |
FCF Conversion (EBITDA) | - | - | - | - | - | 20.96% |
FCF Conversion (Net income) | - | - | - | - | - | 28.15% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/30/18 | 4/30/19 | 6/2/20 | 5/21/21 | 4/29/22 | 4/27/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 1.12 | 2.2 | 2.73 | 2.63 | - | - |
Net Cash position 1 | - | - | - | - | 0.49 | 0.42 |
Leverage (Debt/EBITDA) | -0.9241 x | -2.049 x | -8.505 x | 9.483 x | - | - |
Free Cash Flow 1 | -3 | -3.14 | 0.39 | -3.05 | -4.35 | 0.11 |
ROE (net income / shareholders' equity) | -90.5% | -172% | 265% | -4.9% | -67.8% | -27.1% |
ROA (Net income/ Total Assets) | -5.25% | -6.83% | -4.53% | 2.76% | 3.25% | 3.86% |
Assets 1 | 197.6 | 85.12 | 84.62 | 5.826 | 50 | 9.762 |
Book Value Per Share 2 | 1.890 | 0.1400 | -1.020 | -0.9700 | -0.4800 | -0.3600 |
Cash Flow per Share 2 | 0.4700 | 0.2700 | 0.1300 | 0.1700 | 0.1500 | 0.1300 |
Capex 1 | 0.42 | 0.18 | 0.2 | 0.21 | 0.35 | 0.28 |
Capex / Sales | 4.71% | 4.45% | 12.44% | 11.88% | 18.29% | 14.63% |
Announcement Date | 4/30/18 | 4/30/19 | 6/2/20 | 5/21/21 | 4/29/22 | 4/27/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+3.86% | 9.99M | |
-12.23% | 194B | |
+0.74% | 166B | |
+2.19% | 153B | |
+4.34% | 99.85B | |
+7.04% | 77.56B | |
+19.09% | 73.55B | |
-7.30% | 71B | |
-20.54% | 52.81B | |
+0.53% | 47.86B |
- Stock Market
- Equities
- ALKLA Stock
- Financials Klarsen